Reducing cardiovascular risk and the role of blood pressure: new evidence

Tuesday 2nd September 2008

Reducing cardiovascular risk and the role of blood pressure: new evidence

Munich, Germany

Since the release of the results from the landmark trial ONTARGET^® on March 2008, special attention has been focused on ARBs and telmisartan in particular, on their use in daily clinical practice, and the association of blood pressure control and reduction of cardio & vascular risk. At the second of two satellite symposia, sponsored by Boehringer Ingelheim and Bayer Schering Pharma, new evidence of stroke and kidney disease protection and reduction of cardio & vascular risk in general was presented by a group of renowned international experts from five countries.

The symposium, entitled “Reducing cardiovascular risk and the role of blood pressure: New evidence”, was chaired by Professors Roberto Ferrari (Italy) and Peter Sleight (UK).

The following presentations are available as webcasts under the respective links:

Introduction

Roberto Ferrari, Italy

Targeting blood pressure in the management of total cardiovascular risk

Giuseppe Mancia, Italy

Prevention of stroke: new evidence

Björn Dahlöf, Sweden

Reducing cardiovascular risk: protecting the kidney

Dick de Zeeuw, The Netherlands

Cardio & vascular protection: telmisartan in The ONTARGET^® Trial Programme

Gilles Dagenais, Canada

Panel discussion

All, facilitated by Peter Sleight, UK

^* Telmisartan is currently only approved for the treatment of hypertension

These webcasts follow the presentations held on occasion of the European Society of Cardiology 2008 congress between 30th August - 3rd September 2008. They are reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited.